Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces a significant new client contract win with a leading pharmaceutical company.
Diaceutics’ will collaborate with this new client to produce an outsourced commercial solution for its US market, using the Company’s new DXRX platform to improve patient testing and support the client’s pioneering activities in the field of immunotherapy. This initial contract is worth $1.27 million.
The end-to-end diagnostic development and commercialisation service to be provided to this client evidences the evolution of Diaceutics’ business model. The introduction of DXRX marks the shift from historical consulting and planned platform services to a broader client offering which brings together Diaceutics’ propriety intellectual property, global laboratory network and repository of testing data on one proprietary platform, on a longer term basis. DXRX will enable the client to deliver seamless diagnostic testing for their precision medicine therapies which will result in greater efficiencies and drive increased testing rates and adoption.
Commenting on today’s news, Peter Keeling, Diaceutics’ Chief Executive said: “This client win marks another milestone in the commercial success of Diaceutics. Our data and new commercialisation platform DXRX are designed to provide a full end-to-end service, and via these we believe we are well placed to significantly improve patient testing for our clients’ therapy in this challenging cancer setting.”
